Berylliosis
ICD-10 J63.2 is a billable code used to indicate a diagnosis of berylliosis.
Berylliosis is a chronic lung disease caused by exposure to beryllium, a lightweight metal used in various industries, including aerospace and electronics. Clinically, it presents with respiratory symptoms such as cough, dyspnea, and chest pain, often resembling other interstitial lung diseases. The disease primarily affects the lungs, leading to granuloma formation, which can disrupt normal lung function. The progression of berylliosis can vary; some patients may experience acute symptoms shortly after exposure, while others may develop chronic symptoms years later. Diagnostic considerations include a thorough occupational history, pulmonary function tests, imaging studies (such as chest X-rays or CT scans), and bronchoscopy with biopsy to confirm the presence of beryllium sensitization and granulomas. The disease may also be associated with systemic symptoms, including fatigue and weight loss, complicating the clinical picture. Early diagnosis and management are crucial to prevent further lung damage and improve patient outcomes.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J63.2 specifically covers berylliosis, which is characterized by lung inflammation and granuloma formation due to beryllium exposure. It is important to differentiate it from other pneumoconioses and lung diseases caused by different substances.
J63.2 should be used when there is clear evidence of beryllium exposure and associated respiratory symptoms. It is distinct from other codes for pneumoconiosis, which pertain to different causative agents.
Documentation should include a detailed occupational history, results from pulmonary function tests, imaging studies, and any biopsy results confirming granuloma formation. This evidence is critical for accurate coding and reimbursement.
